No Data
[Brokerage Focus] BOCOM INTL indicates that private Medical Services are seeking steady progress while focusing on investment opportunities amid an aging population and supply-demand mismatch.
Jinwu Financial News | BOCOM INTL released research on the Medical Services sector of the private healthcare industry, indicating that the current focus on investing in the private healthcare services sector is mainly due to 1) valuations having dropped to historical lows, with a recovery in performance growth expected; 2) short-term impacts of reforms likely to gradually clear, while long-term support for the direction of private healthcare services remains unchanged; 3) demographic changes are a key long-term growth driver for the sector. The firm suggests that when selecting investment symbols in the private healthcare services sector, both short-term performance certainty and risks, as well as long-term growth capacity, should be considered while taking into account current valuation levels. The firm's preferred ranking among various specialties is: Traditional Chinese Medicine > Oncology > Ophthalmology > Dentistry >.
Increased shareholding for two consecutive days! This reflects the confidence of Tuhu Ziliang, the founder of Guoshengtang, in the development of the enterprise.
With significant attention from the Capital Markets, Mr. Tu Zhiliang, the major shareholder of Gu Sheng Tang Holdings Limited, expresses his strong confidence in the company's future through his actions. Following his investment of 2,167,070 HKD in the secondary market on January 22 to increase his Shareholding by 80,900 shares, he has made another effort, spending 1,313,803.07 HKD to increase his Shareholding by 49,100 shares yesterday. Not only has he continuously increased his Shareholding, but in fact, Mr. Tu Zhiliang has never implemented any Shareholding since the IPO. This substantial investment in the company's shares clearly demonstrates the major shareholder's firm belief in the long-term development prospects of the company.
The major shareholder has increased their shareholding for the first time! Tu Zhiliang, the founder of Gushengtang (02273), bought 0.0809 million shares in the secondary market.
On January 22, Tsinghua Tongfang Co., Ltd. (02273) shareholder Tu Zhliang invested 2.16707 million Hong Kong dollars to complete a shareholding plan of 0.0809 million shares.
Gushengtang Holdings Limited (2273) Receives a Hold From Jefferies
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
